Lisa G Rider Selected Research

Therapeutics

10/2023	Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial Design.
1/2023	Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy.
7/2018	Pediatric Rheumatology Collaborative Study Group - over four decades of pivotal clinical drug research in pediatric rheumatology.
1/2018	Update on outcome assessment in myositis.
1/2016	Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients.
12/2014	The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.
9/2014	Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.
5/2013	The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis.
2/2013	Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.
3/2012	Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lisa G Rider Research Topics

Disease

67	Myositis (Idiopathic Inflammatory Myopathies) 01/2024 - 07/2002
55	Dermatomyositis (Dermatopolymyositis) 01/2024 - 07/2002
12	Polymyositis 11/2023 - 11/2005
9	Autoimmune Diseases (Autoimmune Disease) 02/2023 - 09/2003
8	Calcinosis 06/2023 - 12/2008
7	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2024 - 07/2013
4	Neoplasms (Cancer) 12/2023 - 11/2005
4	Exanthema (Rash) 11/2023 - 11/2006
4	Inclusion Body Myositis 02/2023 - 11/2005
4	Inflammation (Inflammations) 06/2020 - 03/2012
3	Edema (Dropsy) 11/2023 - 10/2002
3	Systemic Lupus Erythematosus (Libman-Sacks Disease) 06/2022 - 03/2014
3	Infections 04/2022 - 03/2016
3	Rheumatic Diseases (Rheumatism) 01/2022 - 07/2018
2	Ulcer 11/2023 - 01/2022
2	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 10/2023 - 01/2018
2	Rheumatoid Arthritis 10/2023 - 01/2021
2	Systemic Scleroderma (Systemic Sclerosis) 06/2022 - 09/2003
2	COVID-19 01/2022 - 01/2021
2	Deglutition Disorders (Dysphagia) 01/2022 - 10/2021
2	Melanoma (Melanoma, Malignant) 01/2021 - 11/2018
2	Arthritis (Polyarthritis) 01/2021 - 11/2020
2	Arthralgia (Joint Pain) 01/2021 - 07/2013
2	Dysphonia (Spastic Dysphonia) 01/2021 - 07/2013
2	Connective Tissue Diseases (Connective Tissue Disease) 01/2019 - 11/2006
2	Muscular Atrophy (Muscle Atrophy) 12/2013 - 11/2009
1	Fatigue 02/2023
1	Hypersensitivity (Allergy) 01/2023
1	Klinefelter Syndrome (Klinefelter's Syndrome) 06/2022
1	Fatty Liver 04/2022
1	Portal Hypertension 04/2022
1	Thrombocytopenia (Thrombopenia) 04/2022
1	Liver Diseases (Liver Disease) 04/2022
1	Gastroenteritis 04/2022
1	Crohn Disease (Crohn's Disease) 01/2022
1	Cardiomyopathies (Cardiomyopathy) 10/2021
1	Lymphadenopathy 01/2021
1	Contracture 01/2021
1	Infarction (Infarctions) 01/2021
1	Weight Loss (Weight Reduction) 01/2021

Drug/Important Bio-Agent (IBA)

46	AutoantibodiesIBA 01/2024 - 07/2002
10	Rituximab (Mabthera)FDA Link 11/2023 - 02/2013
6	Mi-2 antibodiesIBA 01/2022 - 07/2002
6	Creatine Kinase (Creatine Phosphokinase)IBA 01/2022 - 04/2010
5	Proteins (Proteins, Gene)FDA Link 11/2023 - 11/2006
5	EnzymesIBA 01/2023 - 10/2002
5	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 01/2022 - 01/2006
5	AntibodiesIBA 01/2022 - 02/2006
4	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2016
3	HLA-DRB1 Chains (HLA DRB1)IBA 12/2023 - 03/2006
3	Abatacept (Orencia)FDA Link 11/2023 - 03/2012
3	Complement System Proteins (Complement)IBA 02/2023 - 01/2016
3	InterferonsIBA 01/2023 - 01/2020
3	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2022 - 03/2012
3	VaccinesIBA 01/2022 - 01/2017
3	Interferon Type IIBA 10/2020 - 09/2010
3	sodium thiosulfate FDA Link 01/2020 - 03/2012
3	Ligases (Synthetase)IBA 01/2019 - 11/2006
3	CytokinesIBA 03/2014 - 12/2008
3	Signal Recognition ParticleIBA 03/2014 - 11/2006
2	HLA-DQA1 antigen (HLA DQA1)IBA 12/2023 - 09/2003
2	CalciumIBA 06/2023 - 06/2020
2	Complement C4 (Complement Component 4)IBA 02/2023 - 01/2016
2	ImmunosorbentsIBA 01/2023 - 01/2022
2	SS-A antibodiesIBA 01/2023 - 01/2019
2	5'-Nucleotidase (5' Nucleotidase)IBA 01/2022 - 01/2018
2	Antirheumatic Agents (DMARD)IBA 01/2021 - 11/2020
2	transcriptional intermediary factor 1IBA 01/2021 - 11/2018
2	Methotrexate (Mexate)FDA LinkGeneric 05/2017 - 01/2017
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 05/2017 - 01/2017
2	Prednisone (Sone)FDA LinkGeneric 05/2017 - 01/2017
2	Peptides (Polypeptides)IBA 12/2006 - 11/2005
2	HLA-A Antigens (HLA-A)IBA 03/2006 - 11/2005
1	Etanercept (Enbrel)FDA Link 11/2023
1	HLA-DR3 Antigen (HLA DR3 Antigen)IBA 02/2023
1	Messenger RNA (mRNA)IBA 01/2023
1	Cathepsin DIBA 01/2023
1	MicroRNAs (MicroRNA)IBA 01/2023
1	AcidsIBA 01/2023
1	Galectin 3 (LGALS3)IBA 01/2023
1	Estrogen Receptor alphaIBA 01/2023
1	Deoxyribonuclease I (Nickase)IBA 01/2023
1	Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA 01/2023
1	Interleukin-2 (IL2)IBA 01/2023
1	Carrier Proteins (Binding Protein)IBA 01/2023
1	Transaminases (Aminotransferases)IBA 04/2022
1	FlagellinIBA 01/2022
1	CortactinIBA 01/2022
1	Prostaglandins AIBA 01/2022
1	GlucocorticoidsIBA 10/2021
1	Intravenous Immunoglobulins (IVIG)FDA Link 10/2021
1	nuclear matrix protein 2IBA 01/2021
1	baricitinibIBA 01/2021
1	IFIH1 Interferon-Induced HelicaseIBA 01/2021
1	COVID-19 VaccinesIBA 01/2021
1	Janus KinasesIBA 01/2021

Therapy/Procedure

18	Therapeutics 10/2023 - 11/2002
2	Gas Lasers 01/2020 - 11/2019
2	Aftercare (After-Treatment) 03/2016 - 01/2009
1	Self-Help Devices (Assistive Technology) 01/2022